Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients

Table 2 Patient characteristics at baseline (n = 29) (%)

Patient characteristics	Value
Gender
Female	13 (44.8)
Age (yr), mean (range)	42.3 (19.8-61.1)
Duration of the disease (mo), median (range)	166 (7-365)
Montreal classification:
A1 (< 17 yr)	6 (20.7)
A2 (17-40 yr)	17 (58.6)
A3 (> 40 yr)	6 (20.7)
L1 (ileal)	15 (51.7)
L3 (ileocolonic)	9 (31.0)
L1 + L4 (ileal + upper gastrointestinal)	5 (17.2)
B1 (non-stricturing/penetrating)	9 (31.0)
B2 (stricturing)	14 (48.3)
B3 (penetrating)	6 (20.6)
Perianal disease	10 (34.4 )
Extensive resection	11 (37.9)
Immunomodulators (AZA, 6-MP) concomitant to adalimumab	5 (17.2)
Concomitant enteral nutrition	6 (20.7)
Previous infliximab	15 (51.7)
Previous resections (including index operation)
1	15 (51.7)
2	7 (24.1)
3	6 (20.7)
4	1 (3.4)
Smoking status at diagnosis
Smokers	14 (48.3)
Ex-smokers	2 (6.9)
Non-smokers	13 (44.8)
Smoking status after the index operation
Smokers	4 (13.8 )
Ex-smokers	12 (41.4)
Non-smokers	13 (44.8)

AZA: Azathioprine; 6-MP: 6-mercaptopurine.